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Tyrosinase antibodies recently have been reported to 
occur frequently in patients with vitiligo. We de-
scribe the detection of tyrosinase antibodies in viti-
ligo patients using in vitro 35S-labeled human tyrosi-
nase in a radioimmunoassay. Of 46 vitiligo sera 
examined in the assay, five (10.9%) were found to be 
positive for tyrosinase antibodies . In contrast, 20 
control sera and sera from 10 patients with Hashimo-
to's thyroiditis were negative . Four of the sera posi-
tive in the radioimmunoassay were also positive in an 
ELISA using mushroom tyrosinase as antigen. Ab-
sorption studies indicated that pre-incubation ~ith 
mushroom tyrosinase absorbed out the immunoreac-
tivity of the positive sera in the radioimmunoassay, 
suggesting cross-reactivity, but this absorption was 
never complete, indicating that there are tyrosinase 
antibodies in human sera that do not react with the 
V itiligo is a common skin disorder, the precise etio l-ogy of w hich remains obscure . Som e studies have sh own that an ti-melanocyte autoantibodies are of-ten present in the sera of vitiligo patients (C ui et a/, 1992) and that the re is a correla tion be tween the 
presence and level of these antibodies and the extent (Naughton cl 
a/ , 1986) and activi ty (Haming et a/, 1991) of vitiligo. T hese 
observations and the fac t that these an.tibodies can kill human 
melanocytes ;, vitro (Norris et a/, 1988) su ggest they may be 
involved in the pathogenesis of vitili go, although it is also p.ossible 
tha t antibody production may m ere ly refl ect a secondary immuno-
logic response to m elanocytes damaged by o ther mechanism s. 
R ecent work has tried to identi f:)r th e melan ocyte autoaritigens 
again st which vitiUgo antibodies react. Some o f the an tigens are 
unique to pigmented cells , w hereas o thers are also expressed on 
nonpigmented cells, and all appear to be located on the cell sm·face 
(C ui el a/, 1992). Tyrosinase, a key enzyme iu volved in melanin 
synthesis, has been implica ted as an autoantigen in two studies 
(Song el a/, 1994; Baharav et a/ , 1996), but others have dismissed 
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mushroom protein. There was no obvious association 
between the presence of tyrosinase antibodie s and 
the age of the patients (range: 22-62 y), their duration 
of disease (range: 5-20 y), or the type of vitiligo (one 
segmental, one symmetrical/periorificial, three sym-
metrical), although the three patients with the high-
est antibody levels also had an associated autoim-
mune disorder (one with Graves' disease; two with 
autoimmune hypothyroidism). The results confirm 
that tyrosinase autoantibodies are present in the sera 
of vitiligo patients but at a low frequency. The 
technique described is se nsitive and quantitative and 
allows the detection of confor1national epitopes. I t 
will be useful in longitudinal stu4ies to determine the 
relation between the clinical features of vitiligo and 
tyrosinase antibody levels. K ey wor•d: autoimuuurity. 
J ln11est Demra.tol 109:69-73, 1997 
any role. ' T h e curren t study aimed to analyze vitiligo sera for the 
presen ce of tyrosinase antibodies using a novel radioimm unoassay 
(lUA) ·with 35S-labeled recombinant human tyrosinase. T his type of 
assay recently has been widely used , for example, to detect 
antibodies against glutamic acid decarbo:..-ylase, steroid 21 -hydrox-
ylase, and candida! antigens in insulin-dependent diabetes m ellitus, 
Addison' s disease, and autoimmune polyglandular syndrom e type 
1, respectively (Falorni el a/ , 1994, 199 5; Pe terson el a/, 1996) . 
MATERJ A LS AND METH O D S 
Patients Sera fro m 46 sequen ~ial patients with vitiligo (14 m eu , 32 
wom en; m ean age 48 y, range 23- 79 y) co l.l ected in dermatology and 
endoc rino logy clinics between J anuary ·t 990 and September 1996 were 
used. Pati ents were characterized with respect to th e presence of associated 
autoimmune diseases: 20 had no other d isease and no fa mily hi story of 
autoimmune disease; nin e had no oth er disease bur had a f.1mily history 
of auto irn1n une disease; 17 had an au toi n1n1unc d isord er . Autoin1n1unc 
diseases w ere: Graves' disease, 4; autoimmune h ypothyro idism , 9; alopecia, 
2; Addison' s di sease with hypothyro idism and type 1 d iabetes m elli tus, 1; 
and pernicio us anemia w ith hypo thyro idism , 1. 
Sera from 20 hea lthy laboratory personnel (eight m en , 12 wom e n; age 
range 25-43 y, m ean 33 y) w ere used as contmls. As a further set of 
control s, 10 sera from patien ts (two m en , e ight wom en ; age ran ge 34 - 73 y. 
mean 48 y) with H ashimo to's th yroidi tis bu t wi thou t vitiligo were tested . 
A ll ser a were kept froze n at - zo•c. T he stud)' was approved by the 
' X ie Z, BysuynJC: An ti-tyrosinase an tibodies in vitiligo. ) l twest Dcr111 at"l 
106 :938, 1996 (abstr) . 
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Ethics Committee of the Northern Genera l Hospital, Sheffield, and all 
subjects gave informed consent. 
Rabbit Antisera Rabbit polyclonal antisera aPEP7 (Tsukamoto et a/, 
1992), generated against a synthetic peptide that corresponds to the 
carboxyl terminus of mouse tyrosinase, and aPEP8 (Tsukmnoto et 0/, 1992), 
generated against a synthetic peptide that corresponds to the carboxyl 
terminus of mouse tyrosinase-related protein 2 (TRP2), were a gift of Prof. 
Vincent Hea6ng (National Institutes of Health, Bethesda, MD). · 
Cloning of Human Tyrosinase eDNA into pBluescr~pt A fl'll-
length human tyrosinase eDNA fragment in pRHOHT2 (Takeda et a/, 
1989) was a gift of Prof. Slugeki Slubahara (Tohoku University School of 
Medicine, Sendai, Japan). initially, the eDNA was subcloned into pBiue-
script SK (Stratagene, La Jolla, CA) to allow in 11itro transcription-translation 
of tyrosinase under control of the T7 promoter. · 
Plasmid plU-lOHT2 (1 f.Lg) was cleaved with enzymes Xbal. and Sail 
(Promega, Southampton, U.K.) in a 50-f.LI reaction volume with buffer 
containing 6 mM Tris HCl (pH 7.9), 6 mM MgCl 2 , and 150 mM N~Cl at 
3 7°C for 90 miJl. The fragments generated were resolved on a 1% 
low-melting-point agarose gel (Sambrook eta/, 1989), and the 2-kb DNA 
band contau~ing tyrosinase eDNA was excised and purified using a Wizard 
DNA clean-up system (Promega). Xbal-Sa/I-restricted pBluescript SK (2.96 
kb) was prepared in the same way. Ligations were conducted overnight at 
Hi°C in a 15- /l,l reaction mixture with 1 U ofT4 DNA lig'lse (Promega), 50 
ng of restricted pBluescript SK, 100 ng of tyrosinase eDNA, and buffer 
containing 66 mM Tris HCl (pH 7.6), 6 mM MgCI 2 , 1 mM dithiothreitol, 
and 66 f.LM ATP. A 2-f.Ll aliquot of the ligation mixture was used to 
trm1sfonn 100 f.LI of competent Eschelichin coli XL1Blue (Sambrook et al, 
1989). Transformed cells were selected on LB agar (Sambrook et. a/, 1989) 
containing 50 }Lg ampicillin per ml. Plasmid was prepared from 10 
transformants using a Wizard miniprep DNA purification system (Pro-
mega). After restriction with Xbnl and Sn/1, each plasmid was analyzed by 
agarose gel electrophoresis (Sambrook et nl, 1989) to identify those carrying 
a DNA insert. One appropriate recombinant plasmid was designated 
pBSTYR. The construct was verified by dideoxy sequencing using a 
Seque~ase version 2.0 IGt (Amersham, Aylesbury, U.K.) with [a-3 5SjdATP 
(Amersham) and T7 primer (Prom ega) . Large-scale preparation of pBSTYR 
was done using the Wizard midiprep DNA purification system. 
In Vitro Coupled Transcription-Translation of Human Tyrosinase 
Full-length human tyrosinase was produced ;, 11itro from the eDNA in 
pBSTYR using a TnT T7-coupled reticulocyte lysate system (Promega). 
Plasmid DNA (2 J.Lg) was incubated for 120 ruin at 30°C in 50 J.Ll reaction 
mixture containing 25 f.LI rabbit reticulocyte lysate, 1 f.Ll T7 TnT RNA 
polymerase, 1 f.Ll ami11o acids minus methionine, 40 U RNasin (Promega), 
2 f.LI TnT reaction buffer, ru1d 4 f.LI translation-grade [35S]methiouiJ1e (1000 
Ci/mmol, 1.0 mCi per ml; Amersham). The reaction was stored at -20oc 
until needed. · 
To determine the percentage incorporation of[·15S]methionine, we added 
2 f.Ll of the reaction mixture to 98 f.Ll of1 M NaOH/2% H 20 2 and incubated 
it at 37°C for 10 min. After tins, 900 f.Ll of ice-cold 25% trichloroacetic acid 
(TCA)/2% casamino acids (Difco, Detroit, Ml) was added, and the reaction 
was incubated on ice for 30 miJ1. To collect the precipitated translation 
products, 250 J.LI of the TCA reaction mix was vacuum filtered onto a 
Whatman GF/ A glass fiber filter prewetted with cold 5% TCA. The filter 
was ru1sed tluee times with 1 ml of ice-cold 5% TCA and once with 1 ml 
of acetone and then allowed to dry at room temperature before counting in 
a11 Lilli 1217 Rackbeta liquid scintillation counter. To determine tota.l 
counts per nlli1 (cpm) present u1 the reaction, a 5-f.Ll aliquot of the TCA 
reaction mix was spotted directly onto a filter. T ins was dried for 10 miJ1 
before countiJ1g. The percent incorporation of [35S]metluonine was deter-
nuned as (cpm of washed filter/cpm of unwashed filter X 50) X 100. 
Electrophoretic Analysis and Autoradiography Sodium dodecyl sul-
fute-polyacrylamide gel electrophoresis (SDS-PAGE; Sambrook eta/, 1989) 
of i11 11itro translated products was performed in a 10% polyacrylamide 
resolving gel containing 325 mM Tris HCI (pH 8.8) and 0.1% SDS and a 4'!fo 
polyacrylamide stac!Gng gel containing 125 mM Tris HCI (pH 6.8) and 
0.1% SDS. The gel running buffer contained 25 mM Tris HCI (pH 8.3), 192 
mM glycuJC, and 0.1% SDS. 
A 5-J.LI aliquot of tl1e in uitro translation reaction mixture was added to 20 
f.LI of SDS sample buffer containing 63 mM Tris HCI (pH 6.8), 10% 
glycerol, 2% SDS, 5% 2-mercaptoethanol, and 0.001% bromophenol blue 
and heated to 1 00°C for 2 min before loading a 10-f.LI sample. To visualize 
protein markers, the gel was stained with O.oso;., Coomassie blue in 10% 
glacial acetic acid /25% isopropanol and destained with l 0% glacial acetic 
acid/25% isopropanol, each for 30 min at room te,;1peratqre. The gel was 
then soaked u1 AmplifY scintillant (Amersham) for 30 min at room 
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temperature before drying at 80°C for 2 h on 3 MM filter paper under 
vacuum. Autoradiography was carried out at - 70°C using x-ray film 
(Genetic Research Instrumentation Ltd, Essex, U.K.). Protein molecular 
weight standards (Sigma, Dorset, U.K.) consisted of myosin (205 kDa), 
J3-galactosidase (116 kDa), phosphorylase b (97 kDa), serum albumin (66 
kDa), ovalbumin (45 kDa), carbonic anhydrase (29 kDa), and soybean 
trypsin inhibitor (20.1 kDa). · 
RIA for Tyrosinase Antibodies For each assay, an aliquot of the ill 11itro 
tianslation reaction mixture (equivalent to 15,000-20,000 cpm of TCA 
precipitable material) was suspended in 50 f.Ll immunoprecipitation buffer 
contaiJ1ing 20 mM Tris HCI (pH 8.0), 150 mM NaCl, 1% Triton X100, and 
10 mg aprotinin per ml. Serum was then added to a fmal dilution of 1:1.0 
unless stated otherwise. After incubation overnight witl1 shaking at 4 °C, 50 
f.Ll of proteiJJ G Sepharose 4 fast Flow slnrry (Pharmacia Biotech, Uppsala, 
Sweden), prepared according to the manufacturer, was added and incubated 
for 1 h at 4°C. T he protein 0 Scpharosc-antibody complexes were then 
collected by centrifugation and W<lshed six times for 15 min in immuno-
precipitation buffer at 4°C. Immtmoprecipitated radioactivity was evaluated 
in a liquid scintillation analyzer. Three aliquots of each sample were counted 
and the mean cpm calcula~ed. The SD oftl1e mean was always witlu11 12'Yo. 
For analysis by SDS-PAGE, the protein G Sepharose-antibody complexes 
were resuspended in 100 f.LI SDS sample bulfer, boiled, aud centrifuged, and 
the supematant was recovered for electrophoresis. 
For absorption studies, each positive patient serum at a final dilution of 
1:10 was incubated with either 1 f.Lg, 5 }Lg, 10 f.Lg, 20 f.Lg, or 50 ~g of 
musluoom tyrosinase (Sigma) in 50 f.Ll ofimmunoprecipitation buffer for 2 h 
at 4°C. Bovine serum albumin (Sigma) was used as a control in the same 
amounts. After pre-incubation, 35S-tyrosit1ase was added as above, and the 
lUA was performed as described. 
Enzyme-Linked Immunosorbent Assay (ELISA) for Tyrosinase 
Antibodies Tins was performed essentially as described elsewhere (Ba-
harav et a/, 1996) . Coming polystyrene 96-well microtiter plates (Bibby 
Sterilin Ltd, Mid Glamorgan, U.K.) were coated with 100 f.Ll of mushroom 
tyrosinase at a concentration of 50 f.Lg per ml in buffer contaiJllilg 1.5 mM 
Na2C03 , 3 .5 mM NaHC03 , and 3.0 m.M NaN3 (pH 9.2) and incubated 
oven-right at 4°C. The plates were then washed six times with phosphate-
buffered saline contaiJ1ing 137 mM NaCI, 2. 7 mM KCI, 10.1 mM 
Na2HP04 , 1.8 mM l<H2 P04 (pH 7.4), and Tween-20 at 0 .05% (PBS/ 
Tween) and then blocked with 0.5% gelatin in PBS at room temperature for 
1 h. After wasllli1g six times with PBS/Tween, 100 f.L] of each serum, diluted 
1:50 in PBS/Tween, was added to a well and the plates were incubated at 
37°C for 2 h . T he plates were washed six times with PBS/Tween and then 
100 f.Ll of anti-human lgG (It-chain speciftc) alkaliJJe phosphatase conjugate 
(Sigma), diluted 1:1000 in PBS/Tween, was added for 2 h at room 
temperature. After washing six times in PBS/Tween, 100 f.Ll of Sigma 104 
phosphatase substrate (Sigma) was applied to each well at a concentration of 
1 rng per ml u1 buffer contaiJllilg 11.9 mM Na2C03 , 16 mM NaHC03 , and 
2 .1 mM MgCI2 (pH 9.3). A LabSystems Integrated ETA Management 
System (Life Sciences International , Hampshire, U .K.) was used to read 
absorption at 405 nm. In each assay, sera were tested in duplicate and the 
average value was taken. 
Expression of Tyrosinase Antibody Levels To control for interassay 
variation, we expressed tyrosinase antibody levels as a relative index (TyrAb 
index). A TyrAb index for each serum tested in the RIA was calculated as 
cpm in1munoprecipitated by tested serw11/mean cpm in"lmunoprecipitatcd 
by the 20 healthy controls. Each senun was tested in at least three 
experiments, m1d the mean TyrAb index was calculated from these. The SD 
of the mean was aiways within 12%. The upper level of normal for the assay 
was calculated using tl1e mean TyrAb index + 3 SD of a population of 20 
healthy individuals. 
For rl1e ELl SA, rl1e TyrAb u1dex for eacll serum sample tested was ca.lcu.la ted 
as absorbm1ce at 405 nm for tl1e tested serwn/mean absorbance at 405 nm for 
20 healthy controls. Each serum was tested in at least tlu-ee e>.]Jeciments, and 
tl1e mean TyrAb index was calculated from these. T he SD of the mean was 
always witllli1lO%. The upper level of norma] for the assay was calculated using 
the mean TyrAb i)ldex + 3 SD of a population of 20 heald1y controls. 
RESULTS 
In Vitvo Translation of Recombinant Human Tyrosinase 
and Immunoprecipitation of 35S-Tyrosinase In l!ilro transla-
tion of pBSTYR resulted in an incorporation of e5S]meth.ionine of 
9.3 :± 1.4% (mean :+:: SD) in four separate experiments . The quality 
of the in llitro trapslated tyrosinase was evaluated by SDS-PAGE 
(Fig 1), showing a product with an estimated molecular weight of 
57 kDa, which agrees well with the molecular weight of 56.2 kDa 
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Figure 1. SDS-PAGE of iu vitro translated 35S-tyrosinase and of 
itnmunoprecipitated 35S-tyrosiuase. 355-ryrosi.nasc was produced in 
vilro in a TnT T7-coupled reticulocyte lysate system as described in !11ntcritds 
n111/ Methods. Five microliters of the reaction mixture were added to 20 f • .d of 
SDS sampl e bulle r, and 10 fLI of this mix were then analyzed by SDS-PAGE. 
The inununoreactivity of 35S-tyrosinase \.vas tested using two rabbit poly-
clonal sera: tyrosinasc-spcciftc aPEP7 and T RP2-specific a PEPB. These sera 
were incubated at a dilu6on of 1: l 00 with <Jn aliquot of the in viiro 
trans lation reaction mixture before incubation with protein G Scpharose as 
described in Materials nnd r\lferilorls. Th.c protein G Sepharose-antibody 
complexes were resuspended in l 00 iLl ofSDS sample buffer and boiled, and 
the supernatant was recovered for analysis by SDS-PAGE. Lane '/, in vitro 
translated 35S-tyrosinase; lane 2, 355-tyrosi.nasc immunoprecipitatcd with 
tyrosillase-spec ific a PEP7 antiserum; /nne 3, 355-tyrosinase immunoprecipi-
tated with TR..P2-speciftc tYPEP8 antiserum. 
pred icted from the amino acid sequen ce of the protein (Takeda ef 
a/, 1989). 
The immunoreactivity of the i11 11itro translated recombinant 
human tyrosinase was tested using rabbit antise ra at a 1:100 
dilution . 35S-tyrosinase was immun oprecipitate d by the tyrosinase-
specifi c aPEP7 anti.serurn but not by the TRP2-spccific aPEPS 
antiserum (Fig 1). The average pe rcentage of 35 S-tyrosinase im-
rnunoprecipitated in four assays by the cYPEP7 antiserum was 65 :!:: 
10% (mean :!:: SD) at a dilution ofl:IOO. To test the sen sitivity of 
the IUA, we immunoprecipitated 35S-tyrosinase with serial dilu-
tions of the aPEP7 antiserum. From thjs, the end point dilution of 
the antiserum was 1:18,000. 
RIA of Vitiligo and of Healthy Control Sera Sera from 46 
vjtiligo patients and 20 h ealthy controls, at a dilution of 1:10, were 
tested for their ability to immunoprecipitate 35S-tyrosinase . For 
each serum, a TyrAb index was assigned as the m ean TyrAB index 
of at least three exp eriments with an SD of less than 12'!/o. The 
upper leve l of normal for the lUA (mean TyrAb index + 3 SD of 
20 hea lthy controls) was es timated as a TyrAb index of1.27 (Fig 2). 
None of tbe healthy indiv iduals was positive for tyrosinase 
antibodies. Among 46 vitiligo patients, five (10.9%,) had a TyrAb 
index above 1 .27 (Fig 2) and were con sidered positive for tyrosi-
nase antibodies. Sera from 10 patients with Hashimoto's thyroiditis 
had a 1uean TyrAb index of0.96:!:: 0.10 (mean :!:: SD), and a1! 10 
were negative for antibodies to tyrosinase. 
SDS-PAGE was used to ch eck that the radioactivity immunopre-
cipitated by each of the positive sera was due to 35 S-tyrosi.nase. 
Figure 3 indicates that the fiv e positive sera immunoprecipitated a 
band of the correc t size when compared with that precipitated by 
tyrosinase-specific a PEP7 antiserum. 
T he three most strongly reacting sera were analyzed at dilferent 
dilutions in the RIA along with a group of six h ealthy controls. A 
TyrAb index for each dilution was calculated and plotted as a 
tl.mction of se wm dilution (Fig 4) . For these three sera , saturated 
bindin g was observed at dilutions up to 1:100 . 
ELISA of Vitiligo and of Healthy Sera Using Mushroom 
Tyrosinase Sera from 46 vitiligo patients and 20 healthy indi-
viduals were tested in the ELISA with mushroom tyrosinase. For 
each sample, a TyrAb index was calculated as the mean TyrAb 
index of at least three experiments with an SD of less than 1 0%. 
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Fignre 2. TyrAb index of vitiligo patients, Hashimoto's thyroiditis 
(HT) patients, and healthy controls in the RIA. Sera were incubated 
at a dilution of1 :10 with an aliquot of i11 11itro translation reaction mix before 
in cubation "~th protein G Sepharose :1s described in J\1/nierin/s nllfl .Merlwds . 
T he cpm immunoprecipitated by each serum were determined, and a TyrAb 
index was calculated as cpm inunun.oprecipi tated by scnu11 sample/ mean 
cpm immunoprecipit:ltcd by 20 healthy contro ls. T he TyrAb index shown 
for each serum is the mean TyrAb index of at least three expc•riments, and 
the 'so of the mean was always within 12%. T he rlotrcrllillc show. the upper 
level of normal of l .27 (mean TyrAb index of 20 healthy comrols + 3 SO) 
for the RIA. T he b?.seline data giv ing a TyrAb index of 1 arc 2340 cpm. 
The upper level ofnonmtl tor the E LlSA (mean TyrA b index+ 3 
SD of20 hea lthy controls) was estimated as a TyrAb index of1.96 
(Fig 5). 
All the controls were negative . Of the 46 v itiligo patients, fo ur 
(8.7°/c,) had an antibody index greater than 1.96 and were consid-
ered positive for tyrosinase antibodies. These four were a lso 
positive by the RIA , and the ranking of their reactivity was the 
same in both assays. Patients with Hashimoto 's thyroiditis had a 
m ean TyrAb index of 0.74 :!:: 0.22 (mean :!:: SD), a.nd a.l.l 1.0 sera 
were negative. 
Absorption Studies To detenuin e whether th e immunoreactiv-
ity of sera in the ELlS A and in the JUA was identi ca l, we performed 
absorption studies as described in Materials a11d l\lfer/r ods using th e 
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Figure 3. SDS-PAGE of 35S-tyrosinasc i.mmunoprecipitated witlt 
either vitiligo or healthy scruut. Sera were incubated at a dilution of 
1:10, except for aPEP7, which was used at 1:100, with an aliquot of the i11 
11itro translation reaction mixtm·e before iJlcubation with protein G Sepha-
rose as described in Materials n11rl Met/10ds. T he protein G Sepha.rosc-
antibody complexes were resuspended in I 00 fLI of SDS sample btdfcr aud 
boiled, and the supernatan t was recovered for analysis by SDS-PAGE. 
Lane 1, 3 5S-tyrosinase .immuuoprecipitated with a P.EP7 antiserum; lanes 
2- 6, 355-tyrosinase imnmnoprecipitated with positive vitiligo se ra ; ln11es 
7- 8, 35S-tyrosinase immunoprecipitated with negative vitiligo sera; 
la11cs 9-10, 3 5S-tyrosinase immunoprecipitatcd with healthy control sera. 
72 KEMP ET AL 
4 -·--···-····-·--··--·-·-··----·--·····-----
0 2 3 4 5 6 
Serum dilution (xl0-2 ) 
Figure 4. Dilution curves of the three highest tyrosinase antibody-
positive sera. A dilution series in PBS was made of each of the three most 
positive sera and SL" healthy controls. Five mkroliters of each dilution were 
added to 50 JJ-I of immunoprecipitation buffer containing an aliquot of ill 
11itro translation reaction mix ture, and the RJA was performed as in Materials 
a11d Methods. The TyrAb index for each serum at each dilution was 
calculated as cpm inU11Uuoprecipitated by serum sample/mean cpm immu-
JJOprecipitated by six healthy controls. The TyrAb index of each positive 
serum is plotted as a fm~ction of the serum dilution. Positive serum 1 (•); 
positive serum 2 (e); positive serum 3 (A). 
three most pos1tJ.ve sera. Figure 6 shows the percentage cpm 
immunoprecipitated by each serum in the RIA after pre-incubation 
with varying amow1ts of either mushroom tyrosinase or bovine 
serum albumin. The results indicate that the mushroom tyrosinase 
was able to absorb out the immunoreac tivity of these sera in the 
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Figure 5. TyrAb index of vitiligo patients, Hashimoto's thyroiditis 
(HT) patients, and healthy controls itt the ELISA. Sera were tested for 
d1c presence of tyrosinase antibodies in an ELISA using mushroom tyrosi-
nase as in Materials and Met!Jotls. A TyrAb index for each se rum tested was 
calculated as absorbance at 405 11m for the serum sample/mean absorbance 
at 405 um tor 20 healthy control s. The TyrA b index shown is the mean 
TyrA.b iudex of at !cast three experim ents for ench serum sam pte. and the 
SD of the mean was always withiulO%. The dotted line shows the upper level 
ofnonnat "s 1.96 (mean TyrAb index of20 healthy controls+ 3 SO) for the 
ELISA . T he baseline data giving a TyrAb index of 1 are an absorbance at 
405 nm of 0.398. 
THE JOURNAL Of: lNVESTIGATIV E DERMATOLOGY 
20 
10 
0 ·-f-----.----~----r----r----~~ 
0 10 20 30 40 50 
Amount of MT or BSA (!'9) 
Figure 6. Absorption of tyrosinase antibodies from positive sera 
with mushroom tyrosinase. Each serum, at a final dilution of 1.:10, was 
pre-incubated with either l J..tg, 5 JJ-g, 10 J.Lg, 20 11-g, or 50 11-g of mushroom 
tyrosinase. Bovine serum albumin was used as a control in the same 
amounts. After pre-incubation, 35S-tyrosinase was added and the RlA was 
carried out as described in Materia ls and Methods. The cpm immunoprecipi-
tated are expressed as a percentage of the cpm immunoprecipitated by each 
serum without pre-incubation and are plotted as a function of the amount 
of mushroom tyrosinase (MT) or bovine serum albumin (l3SA) pre-
incubated with the sera . Positive serum 1 + MT <•); positive serum 2 + 
MT (e); positive serum 3 + MT (A); positive serum 1 + BSA (0); positive 
serum 2 + BSA (0 ) ; positive serum 3 + BSA (6 ). 
RIA. T lus was neve r complete, however; there was 58-72% loss of 
reactivity with the highest amount of mushroom tyrosinase used . 
Bovine serum albumin at similar concentrations had no eftect on 
tyrosinase binding in the RIA. 
It was possible tha t proteolytic activity in the mushroom tyrosi-
nase extract was degrading the labeled protein during incubation 
and thereby causing a decrease in cpm in the RIA. To test tlus, w e 
incubated ~ 55-tyrosinase overnight with either 20 fLg or 50 /Lg of 
mushroom tyrosinase and then analyzed the samples by SDS-PAGE 
and autoradiography. D e gradation of 355 - tyrosinase was not de-
tected by this analysis. 
DISCUSSION 
Tyrosinase antibodies have been detected in the sera of p atie nts 
with vitiligo in two previous studies (Song eta/, 1994; Baharav et al, 
1996), implicating the enzyme tyrosinase as an autoantigen. The 
first study used bacte rially synthesized human tyrosinase and im-
munoblotti11g (Song et al, 1994), wluch is a relatively insensitive 
technique and de tects linea r epitopes that are unlikely to be as 
important as conformational epitopes in the pathogenesis of auto-
ilnmune disease . The second study use d mush.room tyrosinase in an 
ELISA (Baharav el al, 1996) . Although this m e thod is sensitive and 
allows the detection of conformational epitopes, the use of mush-
room tyrosinase is UJ1ukely to allow the detection of aJJ epitopes 
present on the human protein. ln contrast to these two studies, 
others have reported the absence of tyrosina se antibodies in all 
vitiligo sera examined by immunoblotting (n = 40), immunopre-
cipitation (n == 20), and ELISA (n = 13) using human melanocyte 
extract as a source of tyrosinase. 2 
Recendy, RIAs have been developed to de tect specific antibod-
ies in the sera of patients with autoimmune disease (falorni et a/, 
1994, 1995; Peterson et a/, 1996). These involve in vitro translation 
2Xie Z, BystrynJC: Anti-tyrosinase antibodies in vitiligo.] !lwest Dermntol 
106:938, 1996 (abstr). 
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and concomitant radiolabeling of the antigen of interest. T he 
method combines sensitivity with the possibility of detecting 
conformational epitopes. It also allows quantitative m easurement of 
the level of antibodies and avoids the n eed to exp ress and purify the 
protein of interest from either bacterial or m ammalian cells. For 
these reasons, we have developed an RJA for the detection of 
tyrosinase antibodies. 
Using coupled in 11itro transcription-translation, we were able to 
produce 35S-Iabeled recombinant human tyrosi11ase. T lus was of 
high quality as evaluated by SDS-PAGE, and contanunation by 
lower-molecular-weight products was nll.rumal. The protein was 
also immunoreactive and could be im.munoprecipitated by specific 
anti-tyrosil1ase antiserum. 
T he technique was used to examine vitiligo and control sera for 
tyrosinase antibodies. Healthy control sera and sera from patients 
with Hashimoto's thyroiditis did not contai11 tyrosinase antibodies. 
Among 46 vitiligo sera tested, five (10.9%) contained tyrosinase 
antibodies. This was a much lower frequency than found in the 
study of S~p.g et a/ (19~4), in wluch 61% ·of vitiligo patients had 
tyrosinase antibodies. T here are sev ~ral possible explanations for 
this discrepancy. The use of immw10blott~ng in the psevious report 
is a m~or difference fro'm our study, and no quantitative data' were 
provided to validate the definition .of positivity. The differences 
may also reflect variations in d1e groups of patients studied, such as 
race and geographic location. In addition, all of the patients in the 
study of Song et nl (1994) had a personal or family history of 
autoinmnme disease, but even considering the 26 sinillar patients in 
the present study, only 3 (11.5 %) had tyrosinase antibodies. 
The state of the disease may also affect the frequency of positive 
sera. In patients with active vitiligo, melaJlocytes are still being 
destroyed, and sera are therefore more likely to have antibodies to 
melanocyte antigens (Harnmg et al, 1991) , although formation of 
immune complexes could theoretically reduce detectability. When 
the disease is inactive, tyrosinase ru1tibodies may decrease to 
undetectable levels. It is difficult, however, to assess the activity of 
vitiligo at a single clliuc visit, and there are no reliable serologic 
markers for activity. These findings suggest that it m ay be word1 a 
prospective study to explore the value of tyrosinase antibody levels 
in this capacity. Finally, it is possible that some epitopes are not 
present on the tyrosrnase used in tl:lls assay, as it may not be properly 
glycosylated in the in 11itro transcription-translation system. T his 
could account for the low frequ ency of tyrosinase antibody-positive 
sera. The tyrosinase used in the study of Song eta/ (1994), however, 
was produced in bacteria and would therefore not be glycosylated 
or processed, as it would be in the melanocyte; yet, still a lugh 
frequency of tyrosinase antibody-positive sera was found. 
Fou1· of the patients positive i11 the R.IA were also positive for 
tyrosinase antibodies in the ELISA using mushroom tyrosinase. T lus 
may have been due to mtibodies reacting with a conformational 
epitope, as the amilw acid homology between mushroom and 
human tyrosinase is low: the region of highest homology between 
the two proteins occurred i11 a 111-amino acid overlap, where 
39.6% sinularity and 23.4% identity w ere found. Incomplete ab-
sorption of antibodies by mushroom tyrosinase (Fig 6) indica ted 
that there may be tyrosinase antibodies in human sera that do not 
react with the mushroom protein, and tlu s could account for the 
negative result i11 one patient in the ELISA. 
TYROSINASE ANTJl30DlES rN VJT lLJGO 73 
T he presence of tyrosinase antibodies in five patients was not 
associated with age (range: 22- 62 y), disease duration (range: 5-20 
y), or the type of vitiligo (one segmental ; one symm etrical / 
pet;orificial; tl1ree symmetrical). With respect to autoimmune 
disorders, the two positive patients with the lowest levels of 
tyrosinase antibodies had no personal or family lustory of associated 
autoimmune diseases. T he three patients with the highest levels had 
an associated autoimmune disorder: Graves' disease in one and 
autoimmune hypothyroidism in two . 
We h ave developed a sensitive, quantitative RlA for tyrosinase 
antibodies based o n radiolabeled human tyr:osi.nase produced in an 
iu IJitro transcription- translation system. ln contras t to a recent 
report testing vitiligo sera for tyrosinase antibodies by immunoblot-
tll1g (Song et a/ , 1994) , the prevalence of tyrosinase an tibodies it~ 
our patients with vitiligo was low (1 0. 9%) and was not confined to 
those with an associated autoimmune disease. T lus RlA should be 
usefnl in clarifying the role of tyrosinase antibodies in the patho-
gen esis of viti ligo. 
T lris IVork wm· mpp01ted by a gmut.fimn tire N01t l1e1'11 Geueral Hospital NHS Tnw 
(Gram 139). Hie would like 10 tlwuk Prof Vir;ceut Henriugfor tlr emrtis~rn o·PEP7 
nud aPEP8, Prof Slr igeki Slriba/rara for the tyrosiuase eDNA, nnd Dr. Riclwrd 
Mclrtloslr for lreljljill disCIIssious duriug tl1e prcparntiou of tlris lll aJIIISCript. 
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